TF and breast carcinoma: In lung and breast carcinoma cells, upregulation of the ZEB1 EMT-TF has been shown to induce the expression of PDL1, an immune-inhibitory checkpoint ligand that suppresses the function of activated T cells through binding to its cognate PD-1 receptor expressed by the latter [77,78].